	US 11,701,397 B2
	*Use of L. reuteri* for recovery of microbiota dysbiosis in early life**
Clara Lucia Garcia-Rodenas, Forel (CH); Bernard Berger, Maracon (CH); Catherine Ngom-Bru, Montpreveyres (CH); Melissa Lepage, Savigny (CH); and Tara Neville, Geneva (CH)
Assigned to BIOGAIA AB, Stockholm (SE)
Filed by BIOGAIA AB, Stockholm (SE)
Filed on May 20, 2022, as Appl. No. 17/749,694.
Application 17/749,694 is a continuation of application No. 15/521,977, granted, now 11,369,646, previously published as PCT/EP2015/075164, filed on Oct. 29, 2015.
Claims priority of application No. 14190941 (EP), filed on Oct. 29, 2014.
Prior Publication US 2022/0331380 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A23L 33/00 (2016.01); A23L 33/135 (2016.01); A61K 35/745 (2015.01); A61K 31/702 (2006.01); A61K 31/733 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01)

CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61K 9/0053 (2013.01); A61K 31/702 (2013.01); A61K 31/733 (2013.01); A61K 35/745 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01); A23Y 2220/71 (2013.01)]

15 Claims

1. A method for treatment or reducing a risk of one or more disorders selected from the group consisting of insulin resistance, type 2 diabetes, peripheral and central adiposity, and obesity, wherein the one or more disorders are associated with microbiota dysbiosis occurring in a young human aged up to three years of age, the one or more disorders occurring in the young human or later in the life of the young human, the method comprising administering Lactobacillus reuteri to the young human, wherein the young human is suffering from the microbiota dysbiosis, and the administering is effective to treat the microbiota dysbiosis.